Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Overview of attention for article published in Clinical Cancer Research, March 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

patent: 1 patent

Readers on

mendeley: 72 Mendeley

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 19,217 followers.

RT @CCR_AACR: Clinical Trial in the March issue: Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carb…

Clinical Trial in the March issue: Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer. https://t.co/1aehbZVQHg https://t.co/egeMR21ucb

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer https://t.co/MyrPUOI1r0

Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer. https://t.co/4bmbcrGhLP

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.